You are here
» Professor Dipti TalaulikarProfessor Dipti Talaulikar
Contacts
Associate Professor Dipti Talaulikar is a visiting fellow in the ACRF Department of Cancer Biology and Therapeutics at The John Curtin School of Medical Research, ANU, Canberra. She leads the Haematology Translational Research Unit at Canberra Hospital with a research focus on lymphoproliferative disorders. Her research program supports research students, and her particular areas of interest lie in dissecting the disease heterogeneity and determining the cellular origin of lymphoma using a combination of sophisticated flow cytometry and cell sorting, next generation sequencing and ultra deep sequencing techniques, establishing links between autoimmunity and lymphoma and determining mechanisms of spread of lymphoproliferative disorders to extranodal tissues especially the bone marrow.
Correlative studies for the NHL29 ALLG multicentre clinical trial are being performed by the group.
She manages the Haematology Research Tissue Bank, which is a repository of peripheral blood, bone marrow and primary tissue samples from patients with haematological and related disorders. A particular strength of the tissue bank is availability of cryopreserved cells for cellular analysis and creation of live cell model systems. Cell pellets, plasma, trizol preparations and paraffin embedded tissue are also available. Our goal is to utilise this resource to promote research within Australia and internationally, and we welcome applications on quality scientific projects from researchers.
Current projects:
1. Disease heterogeneity in NHL
2. BCR and somatic mutations in patients with lymphoma and autoimmunity
3. Characterising the plasma cell compartment in Waldenstrom Macroglobulinaemia
4. Mutations in ribosome biogenesis and MDS
Research interests
Cellular origin of lymphoma: Recent studies have elucidated recurrent somatic mutations in several subtypes of non-Hodgkin lymphoma. However, it is not yet known at what stage in ontogeny these mutations arise. Our group is studying the disease heterogeneity within subtypes of non-Hodgkin lymphoma using sophisticated multicolour flow cytometry, genotyping and ultra deep sequencing techniques. The project involves use of human samples archived in the Haematology research tissue bank, and direct translation of research findings into the diagnostic laboratory and clinic.
Other projects include elucidation of links between autoimmunity and lymphoma, and mechanisms of spread of lymphoma cells to extra nodal tissues especially bone marrow.
Groups
1. Dipti Talaulikar*, Constantine S. Tam*, Doug Joshua, Joy Ho, Jeff Szer, Hang Quach, Andrew Spencer, Simon Harrison, Peter Mollee, Andrew W. Roberts, Noemi Horvath, Cindy Lee, Andrew Zannettino, Ross Brown, Bradley Augustson, Wilfrid Jaksic, John Gibson, Anna Kalff, Anna Johnston, Judith Trotman Akash Kalro, George Grigoriadis, Chris Ward, and H. Miles Prince. Treatment of Patients with Waldenström Macroglobulinaemia: Clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group. Internal Medicine Journal, under review.
2. Colm Keane, Clare Gould, Kimberley Jones, Dipti Talaulikar, David Hamm, Frank Vari, Erica Han, Peter Wood, Kim-Anh Le-Cao, Michael R. Green, Pauline Crooks, Sanjiv Jain, Josh Tobin, Raymond J. Steptoe, Maher K. Gandhi. The T cell Receptor repertoire is a key determinant of the tumour microenvironment and survival in Diffuse Large B cell Lymphoma. Clinical Cancer Research, in press.
3. Andrews TD, Jeelall Y, Talaulikar D, Goodnow CC, Field MA. “DeepSNVMiner: A sequence analysis tool to detect emergent, rare mutations in subsets of cell populations”. PeerJ. 2016 May 24;4:e2074. doi: 10.7717/peerj.2074. eCollection 2016.
4. Colm Keane, Frank Vari, Mark Hertzberg, Kim-Anh Le-Cao, Michael R. Green, Erica Han, John F. Seymour, Rodney J. Hicks, Devinder Gill, Pauline Crooks, Clare Gould, Kimberley Jones, Lyn R. Griffiths, Dipti Talaulikar, Sanjiv Jain, Josh Tobin, Maher K. Gandhi. Ratios of T-cell immune-effectors with tumour associated macrophages and PD-1/PD-L1 axis immune-checkpoint molecules, as prognosticators in diffuse large B cell lymphoma: a population-based study. Lancet Haematol. 2015 Oct;2(10):e445-55. doi: 10.1016/S2352-3026(15)00150-7. Epub 2015 Oct 1.
5. Sawang Petvises, Dipti Talaulikar, Helen C O’Neill. Human spleen contains a novel dendritic-like subset equivalent to mouse. Cell Mol Immunol. 2015 Apr 20. doi: 10.1038/cmi.2015.16
6. Hang Quach, Doug Joshua, Joy Ho, Jeff Szer, Andrew Spencer, Simon Harrison, Peter Mollee, Andrew W. Roberts, Noemi Horvath, Dipti Talulikar, Bik To, Andrew Zannettino, Ross Brown, Laurence Catley, Bradley Augustson, Wilfrid Jaksic, John Gibson and H.Miles Prince. Treatment of Patients with Multiple Myeloma who are Eligible for Stem Cell Transplantation: Position statement of the Myeloma Foundation Australia Medical and Scientific Advisory Group (MSAG). Intern Med J. 2015 Jan; 45(1):94-105.
7. Hang Quach, Doug Joshua, Joy Ho, Jeff Szer, Andrew Spencer, Simon Harrison, Peter Mollee, Andrew W. Roberts, Noemi Horvath, Dipti Talulikar, Bik To, Andrew Zannettino, Ross Brown, Laurence Catley, Bradley Augustson, Wilfrid Jaksic, John Gibson and H.Miles Prince. Treatment of Patients with Asymptomatic Multiple Myeloma and Symptomatic Multiple Myeloma who are Not Eligible for Stem Cell Transplantation: Position statement of the Myeloma Foundation Australia Medical and Scientific Advisory Group (MSAG). Intern Med J. 2015 Mar;45(3):335-43.
8. N. Weber, P. Mollee , B. Augustson, R. Brown, L. Catley, J. Gibson, S. Harrison, P.J. Ho, N. Horvath, W. Jaksic, D. Joshua, H Quach, A.W. Roberts, A. Spencer, J. Szer, D. Talaulikar, B. To, A. Zannettino and H.M. Prince. Management of Systemic Light Chain (AL) Amyloidosis: Recommendations of the Myeloma Foundation of Australia Medical and Scientific Advisory Group. Intern Med J. 2015 Apr;45(4):371-82.
9. Subramaniam K, Yeung D, Grimpen F, J, Joseph J, Fay K, Buckland M, Talaulikar D, Elijah J, Clarke AC, Pavli P, Moore J. Hepatosplenic T-cell lymphoma, immunosuppressive agents and biologicals: what are the risks? Intern Med J. 2014 Mar;44(3):287-90. doi: 10.1111/imj.12363.
10. Eslick R, Talaulikar D. Multiple myeloma: from diagnosis to treatment. Aust Fam Physician. 2013 Oct;42(10):684-8. Review.
11. Chen T, McDonald A, Shadbolt B, Talaulikar D. Precision of histological bone marrow staging in follicular lymphoma and diffuse large B-cell lymphoma. Clin Invest Med. 2012 Dec 1;35(6):E358-64.
12. David P. Phillips, Dipti Talaulikar, Carolyn A. Hawkins, Peter E. Hickman. Utilisation of SFLC assays – how well do we comply with guidelines? Accepted for publication, International Journal of Laboratory Haematology, 2012.
13. McNiven Michelle, Talaulikar D. Establishment of a Conversion Factor for the Cepheid GeneXpert BCR-ABL Assay. Pathology. 2012 Jan;44(1):55-7.